The Claim
In high-risk patients with established atherosclerotic cardiovascular disease who are already on statin therapy, the addition of evolocumab or alirocumab reduces the relative risk of major adverse cardiovascular events by 15% over a treatment period of 2.2 to 2.8 years, as demonstrated in the FOURIER and ODYSSEY Outcomes randomized controlled trials involving nearly 46,000 participants.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with serious heart disease who are already taking cholesterol-lowering pills, adding one of two special drugs (evolocumab or alirocumab) can lower their chances of having a major heart problem—like a heart attack—by about 15% over a few years.
See the scientific wording
In high-risk patients with established atherosclerotic cardiovascular disease on statin therapy, adding evolocumab or alirocumab reduces the relative risk of major adverse cardiovascular events by 15% over 2.2 to 2.8 years, as demonstrated in the FOURIER and ODYSSEY Outcomes randomized trials involving nearly 46,000 participants.
What the research says
1 studyStudy: PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
The study looked at the same drugs in the same kind of patients and found they reduced heart problems by about 15%, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.